Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009

Emerging Infectious Diseases

Volumn 18, Issue 1, 2012, Pages 63-70

  Ladhani, Shamez N ^a   Lucidarme, Jay ^a   Newbold, Lynne S ^a   Gray, Stephen J ^a   Carr, Anthony D ^a   Findlow, Jamie ^a   Ramsay, Mary E ^a   Kaczmarski, Edward B ^a   Borrow, Raymond ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE; GROUPS BY AGE; HEALTH SURVEY; HUMAN; INVASIVE MENINGOCOCCAL CAPSULAR GROUP Y DISEASE; IPXL GENE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENINGOCOCCOSIS; MOLECULAR TYPING; MUTATIONAL ANALYSIS; NEISSERIA MENINGITIDIS; NUCLEOTIDE SEQUENCE; ONSET AGE; PNEUMONIA; SEQUENCE ANALYSIS; UNITED KINGDOM;

ACYLTRANSFERASES; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; ENGLAND; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; MUTATION; NEISSERIA MENINGITIDIS, SEROGROUP Y; POPULATION SURVEILLANCE; TIME FACTORS; WALES; YOUNG ADULT;

EID: 84856582273     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1801.110901     Document Type: Article

References (34)

1. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362:1511-20. doi:10.1056/NEJMra0906357
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51-63. doi:10.1016/j.vaccine.2009.04.063
3. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840-7. doi:10.1128/CVI.00529-09
4. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20-9. doi:10.1016/j.vaccine.2009.04.067
5. Meningococcal Reference Unit, Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference J Med Microbiol. 2006;55:887-96. doi:10.1099/jmm.0.46288-0
6. Borrow R. Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis. 2009;7:219-25. doi:10.1016/j.tmaid.2009.05.003
7. Hahné SJ, Gray SJ, Aguilera J-F, Crowcroft NS, Nichols T, Kaczmarski EB, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet. 2002;359:582-3. doi:10.1016/S0140-6736(02)07716-4
8. Bidmos FA, Neal KR, Oldfield NJ, Turner DP. Ala'Aldeen DA, Bayliss CD. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol. 2011;49:506-12. doi:10.1128/JCM.01322-10
9. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737-43. doi:10.1086/527401
10. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol. 2009;47:3577-85. doi:10.1128/JCM.00936-09
11. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol. 2010;17:919-29. doi:10.1128/CVI.00027-10
12. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. Characterisation of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen, factor H binding protein. Clin Vaccine Immunol. 2011;18:1002-14. doi:10.1128/CVI.00055-11
13. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31:89-96. doi:10.1111/j.1574-6976.2006.00057.x
14. Tzeng YL, Ambrose KD, Zughaier S, Zhou X, Miller YK, Shafer WM, et al. Cationic antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol. 2005;187:5387-96. doi:10.1128/JB.187.15.5387-5396.2005
15. Health Protection Agency. Meningococcal Reference Unit isolates of Neisseria meningitidis: England and Wales, by serogroup and epidemiological year, 1998/99-2008/09. 2011 [cited 2011 Nov 21]. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1234859711901
16. Fransen F, Heckenberg SG, Hamstra HJ, Feller M, Boog CJ, van Putten JP, et al. Naturally occurring lipid A mutants in Neisseria meningitides from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog. 2009;5:e1000396. doi:10.1371/journal.ppat.1000396
17. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report. Emerging Infections Program Network. Neisseria meningitidis, 2009. Oct2010 File-17 Nov 2010. 2010 [cited 2011 Nov 21]. http://www.cdc.gov/abcs/reports-findings/survreports/mening09.pdf
18. Winstead JM, McKinsey DS, Tasker S, De Groote MA, Baddour LM. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin Infect Dis. 2000;30:87-94. doi:10.1086/313617
19. Koppes GM, Ellenbogen C, Gebhart RJ. Group Y meningococcal disease in United States Air Force recruits. Am J Med. 1977;62:661-6. doi:10.1016/0002-9343(77)90867-1
20. Wang JL, Liu DP, Yen JJ, Yu CJ, Liu HC, Lin CY, et al. Clinical features and outcome of sporadic serogroup W135 disease Taiwan. BMC Infect Dis. 2006;6:7. doi:10.1186/1471-2334-6-7
21. Faye A, Mariani-Kurkdjian P, Taha MK, Angoulvant F, Antonios M, Aubertin G, et al. Clinical features and outcome of pediatric Neisseria meningitidis serogroup W135 infection: a report of 5 cases. Clin Infect Dis. 2004;38:1635-7. doi:10.1086/421022
22. Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha MK, et al. The role of particular strains of Neisseria meningitides in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. 2003;37:1639-42. doi:10.1086/379719
23. Centers for Disease Control and Prevention. Serogroup Y meningococcal disease-Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR Morb Mortal Wkly Rep. 1996;45:1010-3.
24. Racoosin JA, Whitney CG, Conover CS, Diaz PS. Serogroup Y meningococcal disease in Chicago, 1991-1997. JAMA. 1998;280:2094-8. doi:10.1001/jama.280.24.2094
25. Le Saux N, Bettinger JA, Wootton S, Halperin SA, Vaudry W, Scheifele DW, et al. Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. Can J Infect Dis Med Microbiol. 2009;20:e130-4.
26. Erickson L, De WP. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26:1159-64. doi:10.1086/520303
27. Jensen ES, Schonheyder HC, Lind I, Berthelsen L, Norgard B, Sorensen HT. Neisseria meningitidis phenotypic markers and septicaemia, disease progress and case-fatality rate of meningococcal disease: a 20-year population-based historical follow-up study in a Danish county. J Med Microbiol. 2003;52:173-9. doi:10.1099/jmm.0.04817-0
28. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-901. doi:10.1086/315158
29. Pålsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology. 2004;113:153-62. doi:10.1111/j.1365-2567.2004.01976.x
30. Fransen F, Hamstra HJ, Boog CJ, van Putten JP, van den Dobbelsteen GP, van der Ley P. The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease. Infect Immun. 2010;78:3177-86. doi:10.1128/IAI.01311-09
31. van der Ley P, Rodenburg G, Fransen F, Bogaert D, Schipper K, Claus H, et al. Naturally occurring lipid A variants among meningococcal carriage and disease isolates. In: Abstracts of the Seventeenth International Pathogenic Neisseria Conference (IPNC); Banff, Canada; 2010 Sep 11-16; Abstract OM12 [cited 2011 Nov 21]. http://neisseria.org/ipnc/history.shtml.
32. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Aricò B, Capecchi B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195:1445-54. doi:10.1084/jem.20020407
33. Comanducci M, Bambini S, Caugant DA, Mora M, Brunelli B, Capecchi B, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun. 2004l;72:4217-23. doi:10.1128/IAI.72.7.4217-4223.2004
34. Nägele V, Heesemann J, Schielke S, Jimenez-Soto LF, Kurzai O, Ackermann N. Neisseria meningitidis adhesin NadA targets β1 integrins: functional similarity to Yersinia invasin. J Biol Chem. 2011; 286:20536-20546. doi:10.1074/jbc.M110.188326